The local medical sector is excited with the introduction of retatrutide, a novel dual GIP and GLP-1 receptor agonist showing remarkable results in clinical trials for managing obesity. This therapy https://getsocialsource.com/story7253903/retatrutide-australia-australia-a-potential-prospect-for-weight-management